ISG-STS 1001
Standard anthracycline-ifosfamide before surgery beat subtype-tailored chemotherapy, and indirectly showed neoadjuvant chemotherapy helps high-risk sarcoma.
Stopped early: 46-month DFS 62% vs 38%, OS 89% vs 64% favouring standard arm (Lancet Oncol 2017). Long-term follow-up (2020-24) confirmed benefit vs historical controls; established 3 cycles of neoadjuvant anthracycline-ifosfamide for FNCLCC grade 3, >5 cm, deep tumours.
Setting
High-risk localised soft-tissue sarcoma of extremities/trunk: neoadjuvant epirubicin-ifosfamide vs histotype-tailored chemotherapy
Phase
Phase 3
Sponsor
Italian Sarcoma Group
Registry
Headline result
Standard arm DFS HR ~0.45 vs tailored; OS 89% vs 64% at 46 months.
Reported
2017
Enrolled
287
In plain words
What these results mean for people, not percentages
Overall survival at 46 monthssurvival endpoint
- 89 vs 64 out of 100 alive at 46 months with Epirubicin-ifosfamide compared with Histotype-tailored; 25 more per 100.
- Roughly one extra person helped for every 4 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
- These results apply to the people the trial enrolled: High-risk localised soft-tissue sarcoma of extremities/trunk: neoadjuvant epirubicin-ifosfamide vs histotype-tailored chemotherapy. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.